Determine the necessary mass, volume, or concentration for preparing a solution.
Ravulizumab (anti-Complement C5) (Ab176615) - SEC
The purity of Ravulizumab (anti-Complement C5) (Ab176615) is more than 95% verified by HPLC.
Ravulizumab (anti-Complement C5) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab (anti-Complement C5) can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Ravulizumab (anti-Complement C5) (Ab176615) - SEC
The purity of Ravulizumab (anti-Complement C5) (Ab176615) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
| Certificate of Analysis | Sep 11, 2026 | Ab176615 | |
| Certificate of Analysis | Sep 11, 2026 | Ab176615 | |
| Certificate of Analysis | May 22, 2026 | Ab176615 | |
| Certificate of Analysis | May 22, 2026 | Ab176615 | |
| Certificate of Analysis | May 22, 2026 | Ab176615 | |
| Certificate of Analysis | Dec 22, 2023 | Ab176615 | |
| Certificate of Analysis | Dec 22, 2023 | Ab176615 |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →